Sofinnova Capital X Fund closed at €472m

The early-stage healthcare venture capital fund, Sofinnova Capital X,was oversubscribed at €472m. This brings the total amount the venture capitalist has raised to €1bn in the last 12 months. Capital X, the 10^th iteration of Sofinnova Partners’ flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.

 Sofinnova Capital X is aimed at investing in tbiopharmaceutical and medical device start-ups that address unmet clinical needs and aim to transform patients’ lives. Capital X was successfully raised with institutional investors including pension funds, insurance companies, foundations, endowments, corporate investors, and prominent family offices from across Europe, Asia, and North America. The Fund welcomed back existing investors and attracted new blue chip limited partners, reflecting sustained confidence in the firm’s capacity to generate strong financial returns. 

Founded in 1972, Sofinnova Partners has backed more than 500 companies. The VC firm has more than €2.5bn under management.